TICKERNERD
Menu
ELDNELDNHealthcare · Biotechnology

ELDN Stock Forecast: Eledon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$3.54
−4.32% on the day

The 6 Wall Street analysts covering Eledon Pharmaceuticals, Inc. hold a median 12-month price target of $8 — +126.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$273.2M
Ticker Nerd rank
32 / 100
Median analyst target
$8.00
Analysts covering
6
Total return, dividends reinvested
1W
−4.1%
1M
−12.6%
YTD
+134.4%
1Y
+36.2%
From 52W high
−18.8%
From 52W low
+154.7%
$1.39
$4.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELDN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eledon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
70
Size
63
Momentum
53
Growth
51
Issuance
36
Quality
35
Value
33
Volatility
30
Revisions
28

Accruals (70): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (28): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELDN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELDN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26ELDNHigh $12.00Median $8.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $7.00Median $8.00High $12.00

The green dot is the last close — the median target sits +126.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 July 2026Rodman & RenshawInitiatesBuy$12
18 Nov 2025GuggenheimMaintainsBuy—
18 Nov 2025GuggenheimMaintainsBuy$9.00 → $8.00
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
25 July 2025Craig-HallumInitiatesBuy—
18 June 2025HC Wainwright & Co.AssumesBuy$9.00
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
7 May 2024HC Wainwright & Co.MaintainsBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
24 Oct 2023HC Wainwright & Co.MaintainsBuy—
27 Sept 2023Noble Capital MarketsInitiatesOutperform—
22 Aug 2023Cantor FitzgeraldReiteratesOverweight—
26 May 2023HC Wainwright & Co.ReiteratesBuy—
1 June 2022SVB LeerinkMaintainsOutperform—
24 Nov 2021HC Wainwright & Co.MaintainsBuy—
27 Apr 2021SVB LeerinkMaintainsOutperform—
23 Mar 2021Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELDN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ELDN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Eledon Pharmaceuticals, Inc. (ELDN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.7×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
2.7×

Cheaper than 38% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−110.7%

Higher than 12% of US stocks

Return on assets
−39.0%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ELDN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELDNEledon Pharmaceuticals, Inc.$273.2M
32
SIONSionna Therapeutics, Inc.$288.3M
34
TRDAEntrada Therapeutics, Inc.$289.6M
51
FULCFulcrum Therapeutics, Inc.$285.4M
33
NMRANeumora Therapeutics, Inc.$291.3M
36
TTRXTurn Therapeutics, Inc.$281.8M
17
IRDOpus Genetics, Inc.$293.8M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eledon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELDN news & analysis

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 13 Aug 2026positive

Eledon Pharmaceuticals reported Q2 2026 financial results, highlighting a successful End-of-Phase 2 meeting with the FDA supporting advancement of tegoprubart into a global Phase 3 kidney transplantation trial expected to begin in late 2026, along with positive long-term data from Phase 2 BESTOW and updated islet cell transplantation trials presented at medical conferences.

Why it matters — An ELDN watcher would care because the FDA's endorsement of a Phase 3 trial for tegoprubart, combined with sustained efficacy data in kidney and islet cell transplantation, marks a pivotal step toward potential commercialization of the company's lead candidate.

Eledon: At The Center Of The Next Medical Frontier

Seeking Alpha · 27 July 2026positive

Eledon Pharmaceuticals (ELDN) is rated Buy, with tegoprubart showing strong promise post-Phase 2 in kidney transplantation. The drug also targets Type 1 Diabetes islet cell transplants and ALS, with potential multi-billion dollar annual revenue if approved.

Why it matters — ELDN watchers would care because tegoprubart represents the company's single core asset with potential in multiple major indications, and the analysis suggests significant upside based on risk-adjusted valuation.

FAQ

Frequently asked questions about ELDN stock

What is the ELDN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Eledon Pharmaceuticals, Inc. have a median 12-month price target of $8, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELDN stock a buy right now?

Of the 6 analysts covering Eledon Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eledon Pharmaceuticals, Inc. 32 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELDN?

As at 15 Aug 2026, Eledon Pharmaceuticals, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (70 of 100).

Will ELDN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +126.0% from the last close, and Ticker Nerd's factor model ranks Eledon Pharmaceuticals, Inc. 32 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELDN stock forecast for 2030?

No analyst covering Eledon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.

How has ELDN stock performed over the past year?

Eledon Pharmaceuticals, Inc. returned +36.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eledon Pharmaceuticals, Inc. do?

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, a humanized anti-CD40L antibody that targets the CD40 ligand pathway, a well-validated biological mechanism for immune regulation.

What is the latest news on ELDN?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights". Eledon Pharmaceuticals reported Q2 2026 financial results, highlighting a successful End-of-Phase 2 meeting with the FDA supporting advancement of tegoprubart into a global Phase 3 kidney transplantation trial expected to begin in late 2026, along with positive long-term data from Phase 2 BESTOW and updated islet cell transplantation trials presented at medical conferences.

Company

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, a humanized anti-CD40L antibody that targets the CD40 ligand pathway, a well-validated biological mechanism for immune regulation. Tegoprubart is being evaluated across multiple therapeutic areas, including kidney allograft transplantation through the Phase 2 BESTOW trial, islet cell transplantation for type 1 diabetes management, and xenotransplantation procedures. The company is also exploring applications in amyotrophic lateral sclerosis treatment. Eledon's clinical development strategy encompasses Phase 2 studies demonstrating promising kidney function outcomes and favorable safety profiles compared to standard immunosuppressive regimens. The company is advancing toward Phase 3 clinical trials and regulatory discussions with the FDA. Eledon maintains active collaborations with leading transplant centers and research institutions to expand its therapeutic potential across multiple indication areas.

CEO Dr. David-Alexandre C. Gros M.D., Ph.D. · 33 employees · United States · https://eledon.com